Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-03-04 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
关于全资子公司项目投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an investment project by a wholly-owned subsidiary of the company. It details the investment amount, project scope, funding sources, and approvals needed. It explicitly states that the investment does not constitute a major asset restructuring or related party transaction. The document includes board meeting resolutions and financial data of the subsidiary but does not contain comprehensive financial statements or detailed financial performance analysis. The document length is 4086 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content focuses on capital investment and project financing updates. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2025-03-04 Chinese
关于召开2025年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2025 first extraordinary general meeting of shareholders (临时股东大会通知公告). It details the meeting date, voting methods (including online voting), agenda items to be discussed, and procedural information for shareholders. It does not contain financial statements, audit results, or detailed financial data. It is not a report itself but an announcement about a shareholders meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-03-04 Chinese
变更募集资金用途的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Xiu Yi Pharmaceutical Co., Ltd. regarding the change in the use of raised funds from a previous project to a new upgraded project. It details the original fundraising, the amount raised, the usage and storage of funds, the reasons for changing the use of funds, the new project details, investment plans, risk analysis, and approvals from the board and supervisory committee. The document is focused on fundraising and capital allocation updates rather than financial results, management changes, or legal matters. It is not a full financial report or earnings release but an update on capital use. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is about 5800 characters, which is sufficient for a substantive announcement rather than a brief notice or report publication announcement.
2025-03-04 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司变更募集资金用途的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a securities company acting as a sponsor regarding the change in the use of raised funds by Anhui Xuyi Pharmaceutical Co., Ltd. It includes specifics about the original and new investment projects, amounts, reasons for the change, and the approval process including board and supervisory meetings. The document references regulatory rules related to securities issuance and fund management, and it contains substantive financial data about the fundraising and its usage. This is not a brief announcement or a certification letter but a comprehensive report on the change in use of capital raised through a public offering. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-03-04 Chinese
第四届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 26th meeting of the 4th Board of Directors of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to related announcements on the official stock exchange platform. The content focuses on board decisions such as changes in the use of raised funds, guarantees for subsidiaries, project investments, and calling a shareholders meeting. There is no detailed financial data or comprehensive report content, but rather a summary of board meeting decisions and voting outcomes. This fits the definition of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (1777 characters), and it is not a report publication announcement or regulatory filing. Therefore, the correct classification is MANG with high confidence.
2025-03-04 Chinese
关于为控股子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing a guarantee for a loan to its controlling subsidiary. It includes details about the guarantee, the subsidiary's financials, the board's approval, and the sponsor's opinion. It is not a financial report, audit report, or earnings release. It is a regulatory announcement about a financing-related guarantee but does not report on capital raising or changes in capital structure directly. It is not a report publication announcement or certification. The document fits best under Capital/Financing Update (CAP) as it concerns financing activities and guarantees related to loans.
2025-03-04 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.